Your browser doesn't support javascript.
loading
Rates and outcomes of testing for lynch syndrome in a national colorectal cancer screening programme.
Cudmore, Jane; Kumar, Lakshman; O'Moráin, Neil; Cullen, Garrett; Horgan, Gareth; Aird, John; Sheahan, Kieran; Winter, Desmond C; Kennelly, Rory; Leyden, Jan.
Afiliação
  • Cudmore J; Department of Gastroenterology, Mater Misericordiae University Hospital, Dublin, Ireland; School of Medicine, University College Dublin, Ireland. Electronic address: jane.cudmore@ucdconnect.ie.
  • Kumar L; Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland.
  • O'Moráin N; Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland.
  • Cullen G; Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland.
  • Horgan G; Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland.
  • Aird J; Department of Pathology, Mater Misericordiae University Hospital, Dublin, Ireland.
  • Sheahan K; School of Medicine, University College Dublin, Ireland; Department of Pathology, St Vincent's University Hospital, Dublin, Ireland.
  • Winter DC; Department of Colorectal Surgery, St Vincent's University Hospital, Dublin, Ireland.
  • Kennelly R; Department of Colorectal Surgery, St Vincent's University Hospital, Dublin, Ireland.
  • Leyden J; Department of Gastroenterology, Mater Misericordiae University Hospital, Dublin, Ireland; School of Medicine, University College Dublin, Ireland.
Cancer Epidemiol ; 82: 102314, 2023 02.
Article em En | MEDLINE | ID: mdl-36608496
ABSTRACT

BACKGROUND:

Lynch Syndrome (LS), the most common cause of hereditary colorectal cancer (CRC), is characterised by pathogenic variants in mismatch repair (MMR) genes. Universal testing of all CRCs for LS can increase detection. Rates and outcomes of testing in Ireland's national CRC screening programme have not been examined previously.

METHODS:

CRCs diagnosed at two screening sites between 2015 and 2020 were identified. Patient records were used to determine if CRCs had been tested for MMR deficiency and if detected, what downstream testing to rule out LS or genetic testing to confirm LS was undertaken.

RESULTS:

Over five years, 206 CRCs were diagnosed. Testing for LS was carried out for 100% of CRCs at site A and 69% of CRCs at site B. Of CRCs tested for LS, 14 (8%) were MMR deficient. After downstream testing for BRAF mutation or hypermethylation of MLH1, three CRCs were identified as potentially LS-related. Of these two individuals declined genetic testing and one was lost to follow-up.

CONCLUSIONS:

By 2020 both sites had implemented universal testing of all CRCs for LS. A small number of individuals were identified as being eligible for genetic testing for LS, however those offered declined testing and one individual was lost to follow up. This highlights the importance of universal testing and the need for referral pathways to ensure all appropriate individuals are referred onwards to genetic services.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Neoplásicas Hereditárias / Neoplasias Colorretais / Neoplasias Colorretais Hereditárias sem Polipose Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Neoplásicas Hereditárias / Neoplasias Colorretais / Neoplasias Colorretais Hereditárias sem Polipose Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article